Pramipexole may be an effective treatment option in essential tremor

Clinical Neuropharmacology

Volumn 35, Issue 2, 2012, Pages 73-76

  Herceg, Mihály ^a   Nagy, Ferenc ^a   Pál, Endre ^b   Janszky, József ^b   Késmárky, Ildikó ^c   Komoly, Sámuel ^b   Kovács, Norbert ^b  

^a Kaposi Mor County Hospital   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c Health Center of City of Pécs   (Hungary)

Author keywords

dopamine agonist; essential tremor; pilot study; pramipexole

Indexed keywords

PRAMIPEXOLE;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; DAYTIME SOMNOLENCE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; ESSENTIAL TREMOR; FEMALE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; BENZOTHIAZOLES; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; ESSENTIAL TREMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 84858757308     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31824687bf     Document Type: Article

References (27)

1. Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord 2010;25(5):534-541.
2. Louis ED. Essential tremors: a family of neurodegenerative disorders? Arch Neurol 2009;66(10):1202-1208.
3. Elble RJ, Deuschl G. An update on essential tremor. Curr Neurol Neurosci Rep 2009;9(4):273-277.
4. Louis ED, Rios E, Henchcliffe C. How are we doing with the treatment of essential tremor (ET)?: Persistence of patients with ET on medication: data from 528 patients in three settings. Eur J Neurol 2010;17(6):882-884.
5. Ondo WG, Jankovic J, Connor GS, et al. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 2006;66(5):672-677. (Pubitemid 43739820)
6. Handforth A, Martin FC, Kang GA, et al. Zonisamide for essential tremor: an evaluator-blinded study. Mov Disord 2009;24(3):437-440.
7. Elble RJ, Lyons KE, Pahwa R. Levetiracetam is not effective for essential tremor. Clin Neuropharmacol 2007;30(6):350-356. (Pubitemid 350307314)
8. Ondo WG, Jimenez JE, Vuong KD, et al. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol 2004;27(6):274-277. (Pubitemid 40066229)
9. Handforth A, Martin FC. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. Mov Disord 2004;19(10):1215-1221. (Pubitemid 39429965)
10. Ferrara JM, Kenney C, Davidson AL, et al. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci 2009;285(1-2):195-197.
11. Pahwa R, Lyons K, Hubble JP, et al. Double-blind controlled trial of gabapentin in essential tremor. Mov Disord 1998;13(3):465-467. (Pubitemid 28221499)
12. Gironell A, Kulisevsky J, Barbanoj M, et al. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol 1999;56(4):475-480. (Pubitemid 29166343)
13. Navan P, Findley LJ, Jeffs JA, et al. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor. Mov Disord 2003;18(11):1324-1331. (Pubitemid 38263318)
14. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002;72(6):713-720. (Pubitemid 34557011)
15. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor, Ad Hoc Scientific Committee. Mov Disord 1998;13(suppl 3):2-23. (Pubitemid 28517753)
16. Elble RJ. Diagnostic criteria for essential tremor and differential diagnosis. Neurology 2000;54 (11 suppl 4):S2-S6. (Pubitemid 30390607)
17. Stacy MA, Elble RJ, Ondo WG, et al. Assessment of interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor. Mov Disord 2007;22(6):833-838. (Pubitemid 46800105)
18. Feher G, Balas I, Komoly S, et al. [Analysis of antiparkinsonian drug reduction after bilateral subthalamic deep brain stimulation]. Ideggyogy Sz 2010;63(9-10):314-319.
19. Szende A, Nemeth R. [Health-related quality of life of the Hungarian population]. Orv Hetil 2003;144(34):1667-1674.
20. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005;14(6):1523-1532. (Pubitemid 40848233)
21. Luo N, Low S, Lau PN, et al. Is EQ-5D a valid quality of life instrument in patients with Parkinson's disease? A study in Singapore. Ann Acad Med Singapore 2009;38(6):521-528.
22. Klivenyi P, Vecsei L. [The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life]. Ideggyogy Sz 2008;61(1-2):42-48.
23. Martinez-Martin P, Jimenez-Jimenez FJ, Carroza Garcia E, et al. Most of the Quality of Life in Essential Tremor Questionnaire (QUEST) psychometric properties resulted in satisfactory values. J Clin Epidemiol 2010;63(7):767-773.
24. Deuschl G, Elble R. Essential tremorVneurodegenerative or nondegenerative disease towards a working definition of ET. Mov Disord 2009;24(14):2033-2041.
25. Louis ED, Honig LS, Vonsattel JP, et al. Essential tremor associated with focal nonnigral Lewy bodies: a clinicopathologic study. Arch Neurol 2005;62(6):1004-1007. (Pubitemid 40973465)
26. Adler CH, Shill HA, Beach TG. Essential tremor and Parkinson's disease: lack of a link. Mov Disord 2011;26(3):372-377.
27. Louis ED, Frucht SJ. Prevalence of essential tremor in patients with Parkinson's disease vs. Parkinson-plus syndromes. Mov Disord 2007;22(10):1402-1407. (Pubitemid 47280624)